Loading stock data…
COYA
$4.18+0.07 (+1.70%)
Market ClosedLast close May 11
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs).
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Coya Therapeutics, Inc. in the Healthcare sector is trading at $4.18. The stock is currently near its 52-week low of $3.71, remaining 22.7% below its 200-day moving average. Technical signals show neutral RSI of 35 and bearish MACD signal, explaining why COYA maintains its current current market pressure. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 35) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$4.18
Potential Upside
5%
Whystock Fair Value$4.39
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus7 analysts
Mean target$15.64+274.2%
Range$14.00 – $18.00
Fundamentals
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Tre...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$103.45M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.52
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-49.33%
Volume
Today's trading volume
144,119
Recent News
NanoViricides to Participate at D. Boral Capital Global Conference in NYC
By Karen Roman NanoViricides, Inc. (NYSE: NNVC) said it will participate at the D. Boral Capital Global Conference, to be held on May 7, 2026, at The Plaza Hotel in New York City. The company’s President and Executive Chairman, Anil R. Diwan, PhD, will offer one-on-one meetings on the same day from 9:45AM to 2:45PM ET. […]
NanoViricides’ Measles Treatment Granted Orphan Drug Designation by FDA
By Karen Roman NanoViricides, Inc. (NYSE: NNVC) said the FDA granted “Orphan Drug Designation” (ODD) to its clinical-stage, antiviral drug NV-387 for the treatment of measles, giving the company seven years of market exclusivity after approval and access to tax credits, among other benefits. There is no approved drug to treat the disease and NV-387 […]
Coya Therapeutics, Inc. (COYA) Upgraded to Buy: What Does It Mean for the Stock?
Coya Therapeutics, Inc. (COYA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Coya Therapeutics Details ALS Combo Immunotherapy Plan, Highlights Early Biomarker Signals in Webinar
Speakers on a Coya Therapeutics (NASDAQ:COYA) webinar outlined the company’s scientific rationale and clinical development plans for an investigational combination immunotherapy in amyotrophic lateral sclerosis (ALS), emphasizing a shift in the field toward more targeted, biology-driven approaches.
Coya Therapeutics to sell 2.522M shares at $4.40 in private placement
Coya Therapeutics (COYA) announced that it has entered into a definitive securities purchase agreement for the purchase and sale of an aggregate of 2.522M shares of its common stock in a private placement at a price of $4.40 per share. The offering is expected to close on or about January 30, subject to the satisfaction of customary closing conditions. The investors in the offering are Dr. Reddy’s (RDY), $10M, and Greenlight Capital, an existing institutional stockholder of the company. The gros